中医药治疗肌萎缩侧索硬化的贝叶斯网络Meta分析
该研究基于35项随机对照试验,采用贝叶斯网络Meta分析评估27种中医药疗法对成人肌萎缩侧索硬化患者功能状态和生活质量的效果。结果显示中医药疗法与常规治疗、利鲁唑单用或联用安慰剂在功能状态上无显著差异,但参麦注射液、肌萎灵注射液、加味四君子汤、神哲降气散等在某些量表上具有较高SUCRA概率。
要点
- 中医药疗法与利鲁唑等相比在功能状态上无显著差异。
- 参麦注射液联合常规治疗在ALSFRS和ALSFRS-R上SUCRA较高。
- 针灸联合康复锻炼及利鲁唑在AALSS和m-Norris上SUCRA较高。
核心结论
- 中医药疗法与常规治疗、利鲁唑单用或联用安慰剂在功能状态和生活质量上无显著差异。
- 肌萎灵注射液、参麦注射液、加味四君子汤、神哲降气散可视为ALS的候选制剂。
研究设计与样本
- 贝叶斯网络Meta分析,纳入35项RCT,涉及27种中医药疗法。
主要发现
- 参麦注射液+常规治疗在ALSFRS上SUCRA为0.735,在ALSFRS-R上为0.870。
- 肌萎灵注射液+安慰剂在ALSFRS上SUCRA为0.868。
- 加味四君子汤单用在ALSFRS-R上SUCRA为0.739。
- 针灸+康复锻炼+利鲁唑在AALSS上SUCRA为0.928,在m-Norris上为0.863。
- 神哲降气散+安慰剂在m-Norris上SUCRA为0.860。
关键数值与推荐
- 主要结局为功能状态(ALSFRS、ALSFRS-R、AALSS、m-Norris量表)。
- 生活质量方面,雷火灸+利鲁唑和肌萎灵注射液+安慰剂对ALSAQ-40有利。
临床怎么用
- 对于ALS患者,可考虑将肌萎灵注射液、参麦注射液、加味四君子汤、神哲降气散作为候选制剂。
- 针灸联合康复锻炼及利鲁唑可能在改善功能状态方面具有较高概率优势。
局限性
- 未来研究应关注真实世界数据以探索长期效应和实际获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the effectiveness of specific Traditional Chinese Medicine (TCM) therapies for Amyotrophic Lateral Sclerosis (ALS) using Bayesian network meta-analysis. METHODS: PubMed, the Cochrane Library, EMBASE, Web of Science, and four Chinese databases up to 15th December 2024 was searched, including RCTs on adult Amyotrophic Lateral Sclerosis patients treated with TCM therapies (Chinese herbal medicine, preparations, non-pharmacological treatments) alone or combined with conventional treatments. Controls included no intervention, placebo, conventional treatments, or combinations. Primary outcomes were functional status (ALSFRS, ALSFRS-R, AALSS, m-Norris scales). Bayesian network meta-analysis compared treatment effects and calculated SUCRA values. RESULTS: Thirty-five RCTs involving 27 TCM therapies were included. No significant differences in functional status or quality of life were found among TCM therapies, ICT, Riluzole alone, and Riluzole plus placebo. For functional status, Shenmai injection + ICT (SUCRA 0.735 for ALSFRS, 0.870 for ALSFRS-R), Jiweiling injection + placebo (SUCRA 0.868 for ALSFRS), Jiawei Sijunzi decoction alone (SUCRA 0.739 for ALSFRS-R), Acupuncture + rehabilitation exercises + Riluzole (SUCRA 0.928 for AALSS, 0.863 for m-Norris) and Shenzhe Jiangqi powder + placebo (SUCRA 0.860 for m-Norris) had the highest probabilities of being superior treatment. For quality of life, Thunder fire moxibustion + Riluzole and Jiweiling injection + placebo for ALSAQ-40 were favorable. CONCLUSION: Despite no significant differences in functional status among TCM therapies, ICT, Riluzole alone, and Riluzole plus placebo, Jiweiling injection, Shenmai injection, Jiawei Sijunzi decoction, and Shenzhe Jiangqi powder may be regarded as candidate preparations for ALS patients. Future research should focus on real-world data to explore long-term effects and practical benefits. SYSTEMATIC REVIEW REGISTRATION: https://inplasy.com/inplasy-2024-8-0050/, identifier INPLASY202480050.
引用
- Shen C, Wu XT, Yin H, et al. Selected traditional Chinese medicines for treating amyotrophic lateral sclerosis: a Bayesian network meta-analysis based on randomised controlled trials. Front Pharmacol. 2026. PMID: 42923269. doi:10.3389/fphar.2026.1706211
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。